Tonix Pharmaceuticals to Present Real-World Fibromyalgia Data at ISPOR 2026 Following TONMYA Launch

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026 highlighting findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will feature real-world insights related to fibromyalgia treatment, following the FDA approval of TONMYA in August 2025 and its subsequent U.S. commercial launch in November 2025. The study aims to provide valuable data on treatment patterns and patient characteristics, which could inform clinical practice and healthcare decision-making.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.

In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The presentation at ISPOR 2026 underscores Tonix’s commitment to generating real-world evidence to support the use of TONMYA and to better understand the fibromyalgia patient population.

For more details, the full press release is available at https://ibn.fm/A3668. The latest news and updates relating to TNXP can be accessed in the company’s newsroom at https://ibn.fm/TNXP.